SCINTIX
Commercial- Indications
- Lung cancer, Bone cancer, Metastatic cancer
Company intelligence / Profile preview
RefleXion Medical has developed the first biology-guided radiotherapy system that uses real-time PET imaging to direct radiation precisely at tumor sites. Its flagship product, the RefleXion X1 with SCINTIX therapy, received FDA clearance in February 2023 for treating lung and bone tumors. Early clinical cases have demonstrated precise targeting of moving tumors while sparing healthy tissue. The company continues expanding access through installations at major cancer centers.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on RefleXion Medical.